The COVID-19 Pandemic: Clinical Information for Ophthalmologists
PDF
Cite
Share
Request
Perspective
VOLUME: 50 ISSUE: 2
P: 59 - 63
April 2020

The COVID-19 Pandemic: Clinical Information for Ophthalmologists

Turk J Ophthalmol 2020;50(2):59-63
1. Selçuk University Faculty of Medicine, Department of Ophthalmology, Konya, Turkey
2. Ege University Faculty of Medicine, Department of Ophthalmology, İzmir, Turkey (E)
3. İstanbul Bilim University Faculty of Medicine, Department of Ophthalmology, İstanbul, Turkey (E)
4. Mersin University Faculty of Medicine, Department of Ophthalmology, Mersin, Turkey
5. Hacettepe University Faculty of Medicine, Department of Ophthalmology, Ankara, Turkey (E)
No information available.
No information available
Received Date: 13.04.2020
Accepted Date: 13.04.2020
Publish Date: 29.04.2020
PDF
Cite
Share
Request

Introduction

The coronavirus epidemic that started in China has rapidly spread to all countries of the world and caused a significant number of deaths. The situation was first reported to the World Health Organization (WHO) China office on December 31, 2019 as an outbreak of pneumonia of unknown cause in the city of Wuhan (population ~11 million) in the Hubei province.1,2,3,4 The disease was believed to have originated in a seafood market, which was closed for disinfection on January 1, 2020. Of 44 cases reported on January 3, 2020, 11 patients had severe disease while 33 patients were stable.2,3 On January 7, 2020, it was determined that the epidemic was caused by a novel coronavirus (nCoV). Thailand reported its first case on January 13 and Japan on January 15, while on January 20 the first case was reported in Korea and 6 were reported dead in the city of Wuhan. Later, it appeared in countries such as the United States, Vietnam, Singapore, and Australia, and spread to the European nations, starting with France on January 25, 2020. The WHO reported that the first cases in Wuhan had been infected via animals, after which the virus was transmitted from person to person and detected in clusters among families.3 On January 30, 2020, the epidemic was recognized as a public health emergency of international concern, and on February 11, 2020, the WHO named the novel coronavirus disease COVID-19. The International Committee on Taxonomy of Viruses named the new virus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and the WHO declared the coronavirus epidemic a pandemic on March 12.4 On April 2, the WHO website reported 896,450 infected individuals worldwide, 206 affected countries, and 45,526 deaths globally.5

In Turkey, a Coronavirus Scientific Committee including academicians working in university departments such as infectious diseases, intensive care, pulmonology, emergency medicine, and public health was formed under the Ministry of Health on January 10, shortly after WHO announced the epidemic.6 Thermal cameras were installed in Turkish airports and additional scanning was implemented, especially for passengers arriving from China. As the epidemic spread to other countries, screening was expanded to include passengers from countries with reported cases, and any individuals showing signs of coronavirus infection were quarantined. In February, flights to all countries with growing outbreaks were suspended. In the first week of March, hand disinfectant stations were placed in mass transit and public areas in some provinces. The first case of COVID-19 in Turkey was announced by the Ministry of Health on March 10, 2020. Schools were closed on March 13 and some other precautions were implemented, such as not allowing spectators at sporting events and requiring special permission for government personnel to leave the country. The first COVID-related death in Turkey occurred on March 15, 2020. As of March 19, all sports, scientific, cultural, and artistic activities have been postponed. Lockdown measures were later introduced, first for individuals over the age of 65, then for those under the age of 20. On April 1, it was reported that 601 healthcare workers were infected and 1 physician had died.6 As of April 2, there were 18,135 infected individuals and 356 deaths in Turkey.

References

1
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382:727-733.
2
WHO Novel Coronavirus (2019-nCoV) situation report-1. 21 January 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4
3
Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
4
World Health Organization. Origin of SARS-CoV-2 (26 March 2020) https://www.who.int/health-topics/coronavirus/who-recommendations-to-reduce-risk-of-transmission-of-emerging-pathogens-from-animals-to-humans-in-live-animal-markets
5
Coronavirus disease (COVID-2019) situation reports. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200402-sitrep-73-covid-19.pdf?sfvrsn=5ae25bc7_2
6
Türkiye’de 2020 koronavirüs pandemisi. https://tr.wikipedia.org/wiki/Türkiye%27de_2020_koronavirüs_pandemisi#cite_note-1Nisan-59
7
Habibzadeh P, Stoneman EK. The Novel Coronavirus: A Bird’s Eye View. Int J Occup Environ Med. 2020;11:65-71.
8
Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24:490-502.
9
Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals. Ocul Immunol Inflamm. 2020;16:1-5.
10
Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221-236.
11
Lu R, Zhao X, Li J, Niu P, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020:22;395:565-574.
12
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
13
Chen NS, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020:15;395:507-513.
14
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Feb 28.
15
Laboratory testing of 2019 novel coronavirus (2019-nCoV)in suspected human cases: interim guidance, 17 January 2020.  https://apps.who.int/iris/bitstream/handle/10665/330676/9789240000971-eng.pdf?sequence=1&isAllowed=y
16
World Health Organization. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected. Interim guidance, 2020 https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125
17
She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clin Transl Med. 2020:20;9:19.
18
Yan A. Chinese expert who came down with Wuhan coronavirus after saying it was controllable thinks he was infected through his eyes China: South China morning post. https://www.scmp.com/news/china/article/3047394/chinese-expert-who-came-downwuhan-coronavirus-after-saying-it-was. 2020.
19
Lai THT, Tang EWH, Chau SKY, Fung KSC, Li KKW. Stepping up infection control measures in ophthalmology during the novel coronavirus outbreak: an experience from Hong Kong. Graefes Arch Clin Exp Ophthalmol. 2020 Mar 3. doi:10.1007/s00417-020-04641-8.
20
Lu CW, Liu XF & Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet. 2020;395:e39.
21
Li JO, Lam DSC, Chen Y, Ting DSW. Novel Coronavirus disease 2019 (COVID-19): The importance of recognising possible early ocular manifestation and using protective eyewear. Br J Ophthalmol. 2020;104:297-298.
22
van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, Wolthers KC, Wertheim-van Dillen PM, Kaandorp J, Spaargaren J, Berkhout B. Identification of a new human coronavirus. Nat Med. 2004;10:368-373.
23
Vabret A, Mourez T, Dina J, van der Hoek L, Gouarin S, Petitjean J, Brouard J, Freymuth F. Human coronavirus NL63, France. Emerg Infect Dis. 2005;11:1225-1229.
24
Loon S-C, Teoh SCB, Oon LLE, Se-Thoe SY, Ling AE, Leo YS, Leong HN. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol. 2004;88:861-863.
25
Chan WM, Yuen KS, Fan DS, Lam DS, Chan PK, Sung JJ. Tears and conjunctival scrapings  for coronavirus in patients with SARS. Br J Ophthalmol. 2004;88:968-969.
26
Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020 Feb 26. doi: 10.1002/jmv.25725.
27
Jun ISY, Anderson DE, Kang AEZ, et al. Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients. Ophthalmology 2020 in Press. https://doi.org/10.1016/j.ophtha.2020.03.026
28
Seitzman GD, Doan T. No time for tears. Ophthalmology 2020, doi: https://doi.org/10.1016/j.ophtha.2020.03.030
29
Choudhary R, Kapoor MS, Singh A & Bodakhe SH (2017): Therapeutic targets of renin-angiotensin system in ocular disorders. J Curr Ophthalmol. 2017;29:7-16.
30
Qing H, Li Z, Yang Z, Shi M, Huang Z, Song J, Song Z. The possibility of COVID-19 transmission from eye to nose. Acta Ophthalmol. 2020 Mar 18. doi: 10.1111/aos.14412.
31
van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. New England Journal of Medicine. 2020.
32
American Academy of Ophthalmology. Alert: Important coronavirus updates for ophthalmologists. https://www.aao.org/headline/alert-important-coronavirus-context
33
Junk AK, Chen PP, Lin SC, Nouri-Mahdavi K, Radhakrishnan S, Singh K, Chen TC. “Disinfection of Tonometers: A Report By the American Academy of Ophthalmology.” Ophthalmology. 2017;124:1867-1875.
34
Marmor MF. COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern? AJOPHT11279_proof, 24 March 2020
35
Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020;11:105938.
36
Marmor M, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123:1386-1394.
37
Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949.
38
COVID-19. Teması olan Sağlık Çalışanlarının Değerlendirilmesi. https://ohsad.org/wp-content/uploads/2020/03/COVID19-TemasiOlanSaglikCalisanlarininDegerlendirilmesi-25032020.pdf.pdf
39
Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği. Klorokin ve Hidroksiklorokinin COVID-19 Hastalarında ve Hastalığın Profilaksisinde Kullanımı Konusunda KLİMİK Derneği Görüşü. 21 Mart 2020 [Erişim Tarihi: 22 Mart 2020].  https://www.klimik.org.tr/koronavirus/klorokin-ve-hidroksiklorokinin-covid-19-hastalarinda-ve-hastaligin-profilaksisinde-kullanimi-konusunda-klimik-dernegi-gorusu/
40
COVID-19 Erişkin Hasta Tedavisi. https://covid19bilgi.saglik.gov.tr/depo/tedavi/COVID19_Eriskin_Hasta_Tedavisi_02042020.pdf
41
COVID-19 Çocuk Hasta Yönetimi ve Tedavisi. https://covid19bilgi.saglik.gov.tr/depo/tedavi/COVID19-_Cocuk_Hasta_Yonetimi_ve_Tedavisi.pdf